BIOTRON LIMITED — Capital/Financing Update 2024

Feb 7, 2024

==> picture [227 x 35] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

8 February 2024

The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000

(2 pages by email)

Dear Madam

R&D Tax Incentive

Biotron Limited (ASX: BIT) is pleased to announce that it has received an R&D Tax Incentive rebate of $1,645,113.64 for the 2022/23 financial year.

The R&D Tax Incentive is an Australian Government program under which companies receive cash rebates for 43.5% of eligible research and development expenditure.

The R&D Tax Incentive rebate results from Biotron’s expenditure on its antiviral drug development programs.

Biotron's Managing Director, Dr Michelle Miller commented: "The R&D cash rebate strengthens the Company's cash position and will support commercialisation activities."

Yours sincerely

==> picture [111 x 71] intentionally omitted <==

Peter J. Nightingale Company Secretary

pjn12074

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and SARS-CoV-2 as well as a promising preclinical program for Hepatitis B Virus. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

This announcement has been approved by the Company’s Managing Director.

Enquiries

Dr Michelle Miller Rudi Michelson Managing Director Monsoon Communications Biotron Limited +61-3 9620 3333 +61-(0)412313329

2